A Placebo-controlled Phase IIa Study of Orally Administered BGC20-0134/Pleneva TM (Structured Lipid) in Patients With RRMS

Trial Profile

A Placebo-controlled Phase IIa Study of Orally Administered BGC20-0134/Pleneva TM (Structured Lipid) in Patients With RRMS

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs BGC 200134 (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors BTG
  • Most Recent Events

    • 09 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database record.
    • 15 Mar 2012 This trial is recruiting in Belgium, France and has discontinued in Germany.
    • 05 Oct 2011 Results from patients who have completed the open-label extension are being analysed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top